A quick Google search shows that they paid $11 billion for the company that sells the drug(Sovaldi), and earned $1.3 billion off of it[1] in 2016. They make half of that in the US, and something like 10% of it in all places that aren't the US, Europe, or Japan. That's a 12% return in 2016, which isn't nearly as good as the comments in this thread would have you believe. It's an okay return, but it wouldn't really be…
Or... $11B was a terrible price to pay, and their desire to recoup their shitty investment still shouldn't be allowed to bankrupt people who just want to live. It's also incredibly obtuse to call $84k a "30% premium" on raising a child. There are so many people who don't (because they can't) spend close to $245k, more that can barely pull it off, and even more that shouldn't have pharma rates kept artificially inflat…
The natural response to that is, "Well, okay then - we won't be investing in lifesaving medication development because we'll have to deal with constant cries of 'You're bankrupting people who just want to live!'" We already see this with antibiotics.
Now, boner pills, on the other hand - that's a smart investment. No one will complain if people can't afford boner pills.